The efficacy of Alirocumab for thin-cap fIbroatheroma in patients with coronary artery disease estimated by optical coherence tomography: single centor, Randomized, Open-label, trial

INTERVENTION: Alirocumab group start with alirocumab 75mg per 2weeks and Rosuvastatin 5mg or more per day standard of care group Rosuvastatin 5mg or more per day CONDITION: vulnerable plaque in patients with coronary artery disease PRIMARY OUTCOME: the difference of fibrous cap thickness from baseline INCLUSION CRITERIA: 1)Patients received PCI for acute coronary syndrome or stable angina 2)Patients had received or started after PCI statin therapy 3)OCT images could obtained and vulnerable plaques were presence 4)Patients over 20 years old 5)Written consent for participation in the study